Synaptogenix Announces Reverse Stock Split to Maintain Nasdaq Listing
- None.
- None.
Insights
The announcement of Synaptogenix, Inc.'s reverse stock split is a strategic maneuver often employed by companies facing delisting threats due to non-compliance with stock exchange minimum bid price requirements. The reduction of outstanding shares from approximately 27.1 million to 1.1 million is a significant consolidation, which typically aims to boost the stock's market price by a proportional amount, in this case, theoretically by a factor of 25.
From a financial perspective, while the reverse split does not inherently change the company's market capitalization or value, it can influence investor perception. The higher per-share price post-split may make the stock more attractive to institutional investors who are prohibited from investing in lower-priced stocks. However, there is also a stigma associated with reverse splits as they can be viewed as a remedial action for companies in distress. Monitoring post-split performance will be essential to gauge market reception and the effectiveness of this strategy in maintaining NASDAQ listing standards.
Reverse stock splits can have varied implications on market dynamics. For Synaptogenix, the immediate effect will be a more manageable and potentially more respectable share price, which can affect both liquidity and volatility. Historically, stocks undergoing reverse splits may experience increased volatility in the short term as traders adjust to the new price levels and liquidity changes.
Long-term implications are less certain and depend on underlying business fundamentals. If Synaptogenix can leverage the reverse split to maintain its listing status and subsequently improve its financial health, the market may respond favorably. Conversely, if the company fails to capitalize on the reverse split with substantive operational improvements, the market's initial optimism may wane, leading to potential long-term underperformance.
Legally, the reverse stock split is executed in compliance with corporate governance and NASDAQ regulations. It's important to note that the split affects all shareholders uniformly, preserving their relative ownership percentages, barring the elimination of fractional shares. Shareholders receiving cash in lieu of fractional shares will need to review the tax implications of this transaction, as it may be considered a taxable event.
Moreover, the company's adherence to providing detailed information on the process for electronic and physical stockholders, as well as adjustments to equity awards and convertible instruments, reflects a commitment to transparency and regulatory compliance. Shareholders should review the materials provided by the transfer agent to ensure their holdings are correctly adjusted post-split.
Common stock will begin trading on split-adjusted basis on April 5, 2024
At the effective time of the reverse stock split, every 25 shares of the Company's issued and outstanding common stock will be converted automatically into one issued and outstanding share of common stock without any change in the par value per share. Stockholders holding their shares electronically in book-entry form are not required to take any action to receive post-split shares. Stockholders owning shares through a bank, broker, or other nominee will have their positions automatically adjusted to reflect the reverse stock split, subject to brokers' particular processes, and will not be required to take any action in connection with the reverse stock split. For those stockholders holding physical stock certificates, the Company's transfer agent, Pacific Stock Transfer Company, will send instructions for exchanging those certificates for shares held electronically in book-entry form or for new certificates, in either case representing the post-split number of shares, and any payments in cash in lieu of fractional shares, if applicable.
The reverse stock split will affect all stockholders uniformly and will not alter any stockholder's percentage interest in the Company's equity, except to the extent that the reverse stock split would result in a stockholder owning a fractional share. No fractional shares will be issued in connection with the reverse stock split. Stockholders who would otherwise hold a fractional share of the Company's common stock following the reverse stock split will receive a cash payment in lieu thereof at a price equal to that fractional share to which the stockholder would otherwise be entitled multiplied by the closing sale price of the common stock on The Nasdaq Capital Market, as adjusted for the reverse stock split, April 4, 2024.
The reverse stock split will reduce the number of shares of SNPX common stock outstanding from 27,133,349 shares, the number of shares outstanding on April 2, 2024, to approximately 1,085,333 shares, subject to adjustment for fractional shares. Proportional adjustments will be made to the number of shares of SNPX common stock issuable upon exercise or conversion of the Company's equity awards, convertible preferred stock and warrants, as well as the applicable exercise or conversion price.
About Synaptogenix
Synaptogenix is a clinical-stage biopharmaceutical company that has historically worked to develop novel therapies for neurodegenerative diseases. Synaptogenix has conducted clinical and preclinical studies of its lead therapeutic candidate, Bryostatin-1, in Alzheimer's disease. Preclinical studies have also demonstrated bryostatin's regenerative mechanisms of action for the rare disease Fragile X syndrome, and for other neurodegenerative disorders such as multiple sclerosis, stroke, and traumatic brain injury. The
Forward-Looking Statements
Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements. These forward-looking statements include statements regarding the timing and effectiveness of the reverse split and the Company's ability to regain compliance with Nasdaq's minimum bid price. Such forward-looking statements are subject to risks and uncertainties and other influences, many of which the Company has no control over. There can be no assurance that the clinical program for Bryostatin-1 will be successful in demonstrating safety and/or efficacy, that the Company will not encounter problems or delays in clinical development, or that Bryostatin-1 will ever receive regulatory approval or be successfully commercialized. Actual results and the timing of certain events and circumstances may differ materially from those described by the forward-looking statements as a result of these risks and uncertainties. Additional factors that may influence or cause actual results to differ materially from expected or desired results may include, without limitation, the Company's inability to obtain adequate financing, the significant length of time associated with drug development and related insufficient cash flows and resulting illiquidity, the Company's patent portfolio, the Company's inability to expand its business, significant government regulation of pharmaceuticals and the healthcare industry, lack of product diversification, availability of the Company's raw materials, existing or increased competition, stock volatility and illiquidity, and the Company's failure to implement its business plans or strategies. These and other factors are identified and described in more detail in the Company's filings with the Securities and Exchange Commission. The Company does not undertake to update these forward-looking statements.
Contact
800-811-5591
ir@synaptogen.com
View original content:https://www.prnewswire.com/news-releases/synaptogenix-announces-reverse-stock-split-to-maintain-nasdaq-listing-302106753.html
SOURCE Synaptogenix, Inc.
FAQ
When will the SNPX stock begin trading on a split-adjusted basis?
What is the new CUSIP number for SNPX common stock post-split?
How many shares of SNPX common stock will be outstanding after the reverse stock split?
Will there be any fractional shares issued after the reverse stock split?
What is the reason behind the reverse stock split?
